What is it about?

Carbonic anhydrases (CAs) are enzymes that are found throughout the body and are involved in converting carbon dioxide (CO2) to bicarbonate (HCO3-). Inhibiting these enzymes selectively has shown promise in developing new drugs for various diseases. We created a series of new compounds containing thiosemicarbazones and tested their ability to inhibit specific human carbonic anhydrase enzymes (hCA I, II, IX, and XII) using a single tail approach. The compounds generally showed strong inhibition of the enzymes, with compound 6b being particularly effective against hCA I, II, IX, and XII. Compound 6e also showed significant inhibition against these enzymes. We conducted molecular docking studies to better understand how the compounds interact with the enzymes and found insights into their binding mechanisms and selectivity.

Featured Image

Why is it important?

We conducted structural modification of SLC-011, the only CA inhibitor in clinical phase II trial, using bioisosterism and elongation of tail-approach to improve the activity against CA isoenzymes. The result showed that our modification led to low nanomolar inhibition of the enzymes, especially hCA II.


I hope this paper could serve as a foundation for the development of novel and more effective therapeutic agents for cancer and other carbonic anhydrase-implicated diseases that will translate into clinical trials.

Istanbul Universitesi

Read the Original

This page is a summary of: Thiosemicarbazone-benzene Sulfonamide Derivatives as Human Carbonic Anhydrases Inhibitors: Synthesis, Characterization, and In silico Studies, Anti-Cancer Agents in Medicinal Chemistry, May 2024, Bentham Science Publishers,
DOI: 10.2174/0118715206290722240125112447.
You can read the full text:




The following have contributed to this page